Abstract | Neuroblastoma is a solid tumour that arises from the developing sympathetic nervous system. Over the past decade, our understanding of this disease has advanced tremendously. The future challenge is to apply the knowledge gained to developing risk-based therapies and, ultimately, improving outcome. In this Review we discuss the key discoveries in the developmental biology, molecular genetics and immunology of neuroblastoma, as well as new translational tools for bringing these promising scientific advances into the clinic.
Neuroblastoma is a rare childhood cancer affecting 10.2 per million children under 15 years of age in the United States, and it is the most common type of cancer to be diagnosed in the first year of life 1 . It is a complex and heterogeneous disease 2 , and many factors, such as age at diagnosis and stage of disease, in addition to the molecular, cellular and genetic features of the tumour, determine whether it will spontaneously regress or metastasize and become refractory to therapy. Over the past decade, advances in the clinical staging of neuroblastoma have improved risk stratification 3 . However, not enough is known about how these disease features relate to its underlying biology and how this can be exploited to improve outcome. Our challenge is to bridge the gap between characterizing the molecular and genetic properties of neuroblastoma and understanding the precursor cells that give rise to the disease, focusing on those features that make the cells susceptible to malignant transformation.
Major efforts over the years have been focused on discovering somatic mutations in human tumours. Targeting therapy to tumour-specific mutations holds the promise of precision and effectiveness in eradicating cancer, while sparing patients the acute and long-term toxicities of chemotherapy and radiotherapy. However, genome-wide searches are uncovering striking differences in the prevalence of mutations among tumour types, from very frequent among melanomas to rare among paediatric cancers such as neuroblastoma [4] [5] [6] [7] . The infrequency of mutations is a major disappointment for those looking for actionable targets from gene mutations and it is also an increasingly apparent hurdle for others hunting for tumour-specific immunity. In adult cancers, such as melanoma, the rich epitope landscape 8 has been successfully exploited for T cell-based therapy; however, in neuroblastoma, with its contrastingly narrow epitope landscape, the classic immunotherapy model may be difficult to apply. Antibody-based, rather than T cell-based, therapies directed towards oncofetal antigens (for example, gangliosides) may provide viable treatment alternatives.
Despite this paucity of recurrent somatic mutations, neuroblastoma is a heterogeneous disease 2 (TABLE 1) . As the search for druggable targets continues (TABLE 2) , a better understanding of the developmental biology of this tumour may offer new insights. Many cellular processes that guide tissue morphogenesis and differentiation have parallel functions in cancer. For example, tumour cells from the same patient can be remarkably heterogeneous and change dramatically during disease progression. This is reminiscent of progenitor cell heterogeneity and unidirectional changes in progenitor competence in developing tissues and organs. As in normal developing cells, tumour cells are sensitive to non-cell-autonomous influences and require a precise balance between differentiation and proliferation for growth and homeostasis. Also, similar to rapidly growing embryonic tissues and organs, tumours are metabolically 'tuned' for biosynthesis and often evade cell death machinery to massively proliferate. Thus, developmental biology and cancer biology are natural partners, although integrating the two fields for therapeutic applications can be daunting.
GD2
A disialoganglioside expressed on tumours of neuroectodermal origin, including human neuroblastoma, melanoma, small-cell lung cancer and many sarcomas, with highly restricted expression on normal tissues (such as the cerebellum and peripheral nerves). Two monoclonal antibody families specific for the oligosaccharide epitope of GD2 have been tested extensively in patients, namely the mouse immunoglobulin G3 (IgG3) antibody 3F8 and its humanized version (hu3F8), and the mouse IgG2a antibody 14G2a and its chimeric (ch14.18) or humanized (hu14.18) forms.
Myeloablative
Bone marrow ablation owing to the loss of haematopoietic stem cells following high-dose radiation or chemotherapy.
In this Review we update our current understanding of the neural crest and cellular origins of neuroblastoma. We discuss the normal differentiation and physiology of the sympathetic neurons, highlighting potential actionable targets that are unique to neuroblastoma. We analyse why an antibody against the ganglioside GD2 in an immunosuppressive microenvironment can become tumoricidal. Looking ahead, we propose a compre hensive translational research 'roadmap' that takes advantage of high-throughput drug screening, new generations of animal models and study designs that mimic real clinical settings. We do not discuss modern evolutions of chemotherapy, including those in the myeloablative setting, which have been summarized extensively by other investigators 9 .
Neural crest origin of neuroblastoma Most neuroblastomas are diagnosed in the abdomen and are associated with the adrenal gland or sympathetic ganglia 1, 2 . On the basis of these common sites of primary disease, and on the cellular and neurochemical features of neuroblastomas, it is widely accepted that the cell of origin for neuroblastoma arises from the sympathoadrenal lineage of the neural crest during development 10, 11 (FIG. 1) .
The neural crest is a remarkable structure that is present only during embryogenesis and that gives rise to diverse cell types, including peripheral neurons, enteric neurons and glia, melanocytes, Schwann cells, and cells of the craniofacial skeleton and adrenal medulla 12 .
Cells arising in the adrenal medulla are postganglionic neurons that have lost their dendrites and axons. Preganglionic neurons from the central nervous system (CNS) connect directly to adrenal medulla cells and stimulate the release of catecholamines (that is, adrenaline, noradrenaline and dopamine). Thus, the adrenal medulla is a ganglion of the sympathetic nervous system. Most neuroblastomas arise in the adrenal medulla or lumbar sympathetic ganglia (65%). Among the rest, the ratio of chest/neck/pelvis (4/1/1) primary tumours resembles that of normal sympathetic ganglia distribution in thoracic/cervical/sacral (12/3/4) regions. A small subset of patients presents with bilateral adrenal neuroblastoma 13 , suggesting that they may have a predisposing genetic lesion and that the bilateral tumours result from two independent genetic lesions in the cells of the left and the right sympathoadrenal lineage, as predicted by Knudson and Strong 14 . Alternatively, it is possible that the initiating genetic lesion occurs very early during development and the tumour-initiating cells migrate bilaterally from the neural crest. Whole-genome sequencing of paired bilateral neuroblastoma tumours could distinguish between these two possibilities.
Familial neuroblastoma. Familial neuroblastoma is rare (<2% of all neuroblastomas) 15 . Mutations in some of the signalling pathways (FIG. 1) that are important for the development of the sympathoadrenal lineage are associated with familial genetic syndromes characterized by defects in development and predisposition to neuroblastoma. The first predisposition mutation identified in neuroblastoma was in paired-like homeobox 2b (PHOX2B) 16, 17 , which encodes a homeodomain transcription factor that promotes cell cycle exit and neuronal differentiation 18, 19 and plays a crucial part in the development of neural crest-derived autonomic neurons. PHOX2B has two polyalanine repeat sequences. Expression of the second polyalanine repeat is associated with congenital central hypoventilation syndrome (CCHS) 20 , whereas non-polyalanine repeat expansion mutations (NPARMs) accompany the neuroblastoma-Hirschsprung disease (HSCR)-CCHS association. Thus, it was proposed that perturbations in the PHOX2B-regulated differentiation pathway in the sympathoadrenal lineage of the neural crest may contribute to neuroblastoma tumorigenesis, and subsequent gene expression studies supported this hypothesis 21 . However, when NPARMs were introduced into the endogenous Phox2b allele in mice, the clinical features of neuroblastoma were not recapitulated, even though most of the clinical features of HSCR and CCHS were observed 22 . A more common lesion associated with familial neuroblastoma is in the anaplastic lymphoma receptor tyrosine kinase (ALK) gene [23] [24] [25] [26] (FIG. 2) . The known natural ligands of ALK include pleiotrophin and midkine 27 , and ALK is expressed in the developing sympathoadrenal lineage of the neural crest 28, 29 , where it may regulate the balance between proliferation and differentiation through multiple cellular pathways, including the MAPK and RAS-related protein 1 (RAP1) signal transduction pathways [30] [31] [32] . In addition, there is evidence to suggest that PHOX2B can
At a glance
• Neuroblastoma is a heterogeneous disease. Over 60% of neuroblastomas are metastatic, and most are diagnosed after 18 months of age, with a substantial number carrying MYCN amplification or α-thalassaemia/mental retardation syndrome X-linked (ATRX) mutation, and/or anaplastic lymphoma receptor tyrosine kinase (ALK) mutation. The rest have fairly few somatic mutations and are highly curable with either surgery alone or surgery and low-dose chemotherapy. Neural crest cells and neuroblastoma share common pathways and genes, including paired-like homeobox 2b (PHOX2B), MYCN and ALK.
• A predictive profile of genetic predisposition to neuroblastoma is emerging via genome-wide association and whole-genome sequencing analyses. However, in contrast to adult cancers, there is a general paucity of recurrent somatic mutations in neuroblastoma.
• The biology of catecholamine transport has been successfully exploited to provide the tumour-specific neurotransmitter analogue meta-iodobenzylguanidine (MIBG) for diagnosis and anti-neuroblastoma therapy. This advance shows how understanding unique tumour physiology can lead to new therapeutics that are not directly related to specific genetic lesions.
• Chromosomal aberration is common in neuroblastoma; numerical whole-chromosomal gains are typically found in low-risk tumours, whereas segmental chromosomal gains or losses and somatic mutations are associated with high-risk disease.
• Research on epigenetic regulation and microRNA control may uncover new prognostic markers and therapeutic targets for neuroblastoma.
• Neuroblastoma can evade T cells and natural killer cells while exploiting inflammatory macrophages to enhance its survival. Monoclonal antibodies, cytokines and multifunctional antibodies could potentially reactivate antitumour activity in these cells.
• Anti-GD2 antibodies, when combined with granulocyte-macrophage colonystimulating factor with or without interleukin-2, are one of the most successful and important strategies for the curative approach to neuroblastoma. Both myeloid effectors and natural killer cells and their cell-surface activating or inhibitory receptors have crucial roles in the clinical response.
Adrenal gland
Endocrine organ responsible for generating stress hormones, aldosterone and androgens.
Sympathetic ganglia
Masses of nerve cells that are part of a network controlling autonomic 'fight-or-flight' responses.
Congenital central hypoventilation syndrome
(CCHS). A congenital brain stem disease in which autonomic control of breathing is defective, resulting in sleep apnoea.
Hirschsprung disease
(HSCR). A congenital disease in which the large intestine lacks innervation.
directly regulate ALK gene expression 33 , providing a connection between these two pathways that are mutated in familial neuroblastoma. Furthermore, ALK signalling may be important for the proliferation of the sympathoadrenal lineage during development 34 . Although the ALKactivating mutation F1174L contributes to neuroblastoma tumorigenesis in mice [35] [36] [37] , this specific mutation has not yet been found in familial neuroblastoma, and it seems to behave like a superactivator that is not tolerated in the germ line.
Sporadic neuroblastoma. Approximately 6-10% of sporadic neuroblastomas carry somatic ALK-activating mutations, and an additional 3-4% have a high frequency of ALK gene amplification 6, [23] [24] [25] [26] . These findings in familial and sporadic neuroblastoma suggest that ALK is an oncogenic driver in neuroblastoma, and activating ALK mutations or amplifications, especially in the presence of MYCN amplification, are associated with lethal disease 35, 38 . ALK is a promising target for molecular therapy in preclinical studies and clinical trials for neuroblastoma 39 (TABLE 2) .
However, the most common focal genetic lesion in sporadic neuroblastoma is the amplification of MYCN (≥ten copies for diploid genome or >fourfold signal relative to chromosome 2), which occurs in approximately 22% of tumours and is associated with poor outcome 2 . MYCN regulates the proliferation, growth, differentiation and survival of cells in the developing CNS. It is expressed in the developing neural crest, and several signalling pathways regulate its expression (for example, Hedgehog signalling) 40 . Ectopic expression of MYCN in the sympatho adrenal lineage, under the regulation of the tyrosine hydroxylase promoter, is sufficient to drive neuroblastoma tumorigenesis in zebrafish 41 and mice 42 . Although MYCN is a major oncogenic driver in neuroblastoma and has been extensively studied for nearly three decades 43 , there are currently no clinical trials targeting the MYCN protein directly in neuroblastoma because of the difficulties that are inherent to developing therapies that directly target transcription factors. However, recent efforts have focused on targeting signalling pathways that are involved in deregulating MYCN, such as aurora kinase A 44 and the bromodomain and extraterminal (BET) domain family of proteins 45 (TABLE 2) .
Mutations in α-thalassaemia/mental retardation syndrome X-linked (ATRX) are among the most common lesions in sporadic neuroblastoma. ATRX encodes a SWI/SNF chromatin-remodelling ATP-dependent helicase 4, 5 (FIG. 2) , and ATRX mutations are associated with X-linked mental retardation (XLMR) and α-thalassaemia, suggesting that ATRX functions in various developmental processes. However, little is known about how ATRX contributes to the development or differentiation of the sympathoadrenal lineage. Children with XLMR do not have an increased incidence of neuro blastoma, suggesting that ATRX mutations alone are not sufficient to promote tumorigenesis. However, there is an important association between ATRX mutations and age at diagnosis of neuro blastoma 5 . Very young children (<18 months of age) with stage 4 disease tend to have a better prognosis than their older counterparts, and no ATRX mutations have been identified in this age group. ATRX mutations occur in 17% of children aged between 18 months and 12 years with stage 4 disease, and in 44% of patients older than 12 years who uniformly have a very poor prognosis. The relationship between age at diagnosis and ATRX mutations is significant 5 , but analysis of the prognostic impact of ATRX mutations on survival will require a much larger study. To date, ATRX mutations have not been identified in tumours with MYCN amplification 4, 5 . The relationship between ATRX mutations and abnormal telomeres highlights the importance of telomere content in neuroblastoma. Cancer cells must maintain telomeres for survival 46 . One mechanism of maintaining telomeres in neuroblastoma is through increased expression of telomerase. Telomerase, which . Since 2010 anti-GD2 antibody therapy has been incorporated as the standard of care for patients with high-risk neuroblastoma 119 . § Although most locoregional neuroblastomas are treated with surgery alone for low-risk disease, a small subset requires chemotherapy because of unfavourable biology 1, 3 .
||
Neuroblastoma in adolescent and young adults is indolent, with overall survival at 10 years of <10% 5, 184 . Preclinical ALK, anaplastic lymphoma receptor tyrosine kinase; ALT, alternative lengthening of telomeres; ATRX, α-thalassaemia/mental retardation syndrome X-linked; BET, bromodomain and extraterminal; CAR, chimeric antigen receptor; CASPs, caspases; CDK, cyclin-dependent kinase; ch, chimeric; CHK1, checkpoint kinase 1; DCR, decoy receptor; DR, death receptor; EMT, epithelialmesenchymal transition; GLUT1, glucose transporter type 1 (also known as SLC2A1); GM-CSF, granulocyte-macrophage colony-stimulating factor; HDAC, histone deacetylase; HGF, hepatocyte growth factor; HIF, hypoxia-inducible factor; HLA, human leukocyte antigen; hu, humanized; IFNγ, interferon-γ; IGF, insulin-like growth factor; IGFR, IGF receptor; IL, interleukin; KIR, killer cell immunoglobulin-like receptor; MAb, monoclonal antibody; MMP, matrix metalloproteinase; NK, natural killer; NKT, natural killer T; RASSF1A, RAS association domain-containing protein 1; TAM, tumour-associated macrophage; TRK, tyrosine kinase receptor; VEGF, vascular endothelial growth factor. *Though being assigned under a single hallmark, a specific target could be responsible for multiple hallmarks of high-risk neuroblastoma. ‡ US Food and Drug Administration-approved agents for non-neuroblastoma indications. 
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Chromaffin cells
Neuroendocrine cells in the adrenal medulla that receive sympathetic input and release catecholamine neurotransmitters to the systemic circulation.
Event-free survival
A measure of time spent alive without a life-threatening adverse event.
is composed of a catalytic subunit (telomerase reverse transcriptase (TERT)), an RNA template (telo merase RNA component (TERC)) and dyskerin (DKC1), elongates telomeric repeats at chromosomal ends 46 . Telomerase activity is strongly associated with TERT and TERC expression 47 . High telomerase activity is found in 30% of neuroblastomas at diagnosis and is predictive of reduced event-free survival and overall survival in multivariate analyses 48, 49 . However, telomere length does not necessarily correlate with telomerase activity 50 . In some tumour cells, a homologous recombination-based mechanism of telomere maintenance and elongation is activated. This alternative lengthening of telomeres (ALT) pathway is often indicated by the presence of longer telo meres, and by a strong ultra-bright telomere signal in tumour cells visulaized using fluorescence in situ hybridization. Most of the tumours with ATRX mutations show evidence of ALT, and it is possible that this is a direct effect of defects of histone H3.3 deposition at telomeres. ATRX loss in somatic cell hybrids segregates with ALT activation 51 , but whether ATRX functions in epigenetic processes that are important for sympathoadrenal lineage development or neuroblastoma differentiation remains unknown. Both males and females were found to have ATRX mutations in the original analyses, but additional studies will be required to determine whether there is any gender bias for ALT mediated through ATRX mutations in neuroblastoma. ATRX mutations have not yet been modelled in mice, and no molecular therapies have yet targeted this pathway.
Using whole-genome sequencing, recurrent genetic lesions have been reported in the RAC-RHO pathway 4, 6 , and in chromatin-remodelling genes AT-rich interactive domain 1A (SWI-like) (ARID1A) and ARID1B 7 . Additional studies will be required to elucidate the role of these genes in neuroblastoma initiation and/or progression and the prognostic significance of disruptions in these pathways. Ongoing genome-wide association studies have identified additional pathways that contribute to neuroblastoma initiation and/or progression. Several predisposing single-nucleotide polymorphisms (SNPs) within or adjacent to genes have been identified: long intergenic non-protein coding RNA 340 (LINC00340), the uncharacterized LOC729177, BRCA1 associated RING domain 1 (BARD1) 52 , LIM domain only 1 (LMO1) 53 , dual specificity phosphatase 12 (DUSP12), hydroxysteroid (17-beta) dehydrogenase 12 (HSD17B12), DEAD-box polypeptide 4 (DDX4) and interleukin-31 receptor A (IL31RA) (at the same locus) 54 , HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 (HACE1) 55 and lin-28 homologue B (LIN28B) 55, 56 . The BARD1 SNP effect has been confirmed in African-American children 57 , and the BARD1β isoform 58 and LIN28 59 are oncogenic in neuroblastoma. Taken together, these genomic studies have identified only a few recurrent genetic lesions in druggable pathways. The major new challenge we face is to further elucidate the underlying biology of the tumours to identify deregulated developmental, epigenetic or metabolic pathways that can be therapeutically exploited for patients with high-risk or recurrent neuroblastoma.
Neuronal differentiation in neuroblastoma. Analyses of familial neuroblastoma, polymorphisms found by genome-wide association studies and recurrent somatic mutations found by whole-genome sequencing have greatly enriched our understanding of neuroblastoma and in some cases have identified valuable targets for therapy. Another line of investigation is the unique physiology that is associated with the neuronal differentiation of the sympathoadrenal lineage. A valuable connection between cellular differentiation and . Some cells (red) migrate towards the dorsal aorta as they commit to the sympathoadrenal lineage. This migration is partly directed by the expression of CXC chemokine receptor 4 (CXCR4) on the migrating neural crest progenitor cells (red) and the expression of the stromal cell-derived factor 1 (SDF1) chemoattractant on the dorsal aorta. At the dorsal aorta, the migrating neural crest progenitor cells committed to the sympathoadrenal lineage initiate their differentiation programme in response to bone morphogenetic protein (BMP) signalling 179, 180 . Some of the key transcription factors involved in the initial differentiation at the dorsal aorta are shown in the top grey box. From that point, the cells commit to becoming adrenal chromaffin cells or sympathetic ganglia. Enzymes involved in catecholamine biosynthesis, such as tyrosine hydroxylase (TH) and dopamine β-hydroxylase (DBH), are upregulated at this stage of differentiation of the sympathoadrenal lineage. It is thought that MYCN is expressed throughout this process in the migrating trunk neural crest cells that subsequently commit to the sympathoadrenal lineage. A detailed analysis of anaplastic lymphoma receptor tyrosine kinase (ALK) signalling in the mammalian trunk neural crest with respect to the entire sympathoadrenal lineage has not yet been undertaken. GATA, GATA-binding protein; HAND2, heart and neural crest derivatives-expressed protein 2; INSM1, insulinoma-associated protein 1; PHOX, paired-like homeobox; SOX, sex-determining region Y-box. Nature Reviews | Cancer 
Schwannian stromal content
Glial cells in the surrounding stroma, interspersed with neuroblastoma cells. Tumours that are highly differentiated usually have a high Schwannian stromal content.
Mitotic-karyorrhexis index
A measure of the frequency of cells in mitosis with karyorrhexis (nuclear fragmentation associated with cell death).
tumori genesis has come from the Shimada histologygrading system for neuroblastoma, in which the degree of differentiation, the Schwannian stromal content and the mitotic-karyorrhexis index help to stratify patients into risk groups 60 . The seminal observation that neuronal differentiation is driven by retinoids in vitro 61 has led to 13-cis-retinoic acid (isotretinoin) becoming the standard of care for high-risk neuroblastoma 62 .
Another connection between neuronal differentiation and tumorigenesis is highlighted by the identification of GD2 on the neuroblastic but not the glial lineage 63 of neuronal stem cells 64 , and on neuroblastoma tumours 65, 66 . Oncofetal differentiation antigens, such as GD2, are promising targets for antibody-based therapy (see below).
Another important clue about the relationship between normal differentiation and neuroblastoma origins comes from secreted catecholamine metabolites in patients' urine. Catecholamines are found in the cells of the adrenal medulla and paraspinal ganglia 67 , and neuroblastoma cells often have dense core vesicles (DCVs) in which catecholamines are stored. Meta-iodobenzylguanidine (MIBG), an analogue of noradrenaline, is readily taken up by neuroblastoma cells, and a proportion of it is stored in DCVs 68 . Thus, radioiodinated MIBG is used for diagnostic ( Catecholamine metabolism occurs in these cells as a result of leakage from the DCVs 67, 70 , unless the catecholamines are actively transported back into the DCVs by vesicular monoamine transporters (VAMTs). The conversion of cytoplasmic catecholamines into toxic aldehydes can potentially be exploited for neuroblastoma therapy. In sympathetic neurons, 90% of the dopamine is converted to noradrenaline by dopamine β-hydroxylase (DBH) and stored in DCVs 67 . Dopamine is oxidized by monoamine oxidase (MAO) to 3,4-dihydroxyphenylacetaldehyde (DOPAL), a toxic catecholaldehyde that is rapidly detoxified to 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase 67 . Noradrenaline or adrenaline is metabolized by MAO to 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL), another toxic aldehyde, which is detoxified by aldehyde reductase. Whereas sympathetic ganglia express only MAO, adrenal medulla cells express both MAO and catechol-O-methyltransferase (COMT). In these ganglia, the noradrenaline and adrenaline that leak from DCVs are metabolized by COMT to metanephrines or converted to DOPEGAL by MAO. Although there are differences in the metabolism of catecholamines in adrenal medulla and sympathetic ganglia, both cell types rely on the storage of catecholamines in DCVs by VAMTs.
VAMTs belong to the major facilitator transporter superfamily (MFS) 71, 72 . Both MFS and the ATP-binding cassette (ABC) drug transporter superfamily are highly 
Hyperdiploidy
Having more than the diploid number of chromosomes, where the DNA index is >1. 15. evolutionarily conserved 72 . The driving force for VAMTs is a hydrogen electrochemical gradient produced by an ATP-dependent vesicular proton pump 67 ; any change in ATP production or intracellular pH can tilt this delicate balance against the tumour cell and may provide novel therapeutic approaches for neuroblastoma. For example, ouabain is a (Na + +K + )ATPase inhibitor that lowers intracellular pH and perturbs the electrochemical gradient that sequesters catecholamines in DCVs, thereby reducing the viability of neuroblastoma cells 73 . It is well known that multidrug resistance (MDR) of cancer cells is mediated by members of the ABC transporter superfamily. Although these transporters are prognostic of clinical outcome in neuroblastoma 74 , they may also affect tumour progression through mechanisms other than drug efflux 75 . These observations underscore how a deeper understanding of the unique cellular physiology and metabolism of neuroblastoma can lead to new therapeutics that are not directly related to any particular genetic lesion.
Chromosomal instability A patient's age at diagnosis, stage of disease and the presence of MYCN amplification in neuroblastoma cells are the three strongest determinants of clinical outcome 3 (TABLE 1) . These determinants, combined with the loss of chromosome 11q, tumour histology and ploidy, are now the foundations of risk-group stratification for patients with neuroblastoma. Not surprisingly, neuroblastoma is much more heterogeneous when examined at the genetic level. As with other cancers, non-genetic heterogeneities (for example, epigenetic or differentiation state) also influence risk 76, 77 . However, how heterogeneity evolves with treatment and disease progression remains unknown.
In general, low-risk, intermediate-risk and stage 4S neuroblastomas have numerical chromosomal gains, whereas high-risk neuroblastomas have intrachromosomal rearrangements 1 . The incidence of these chromosomal aberrations increases with age at diagnosis and is strongly prognostic of outcome 4, 5, 49 . Together with oncogene amplifications, these large-scale genomic alterations may lead to the deregulation of mRNAs, microRNAs and other non-coding RNAs that interfere with apoptosis, differentiation and immune surveillance [78] [79] [80] . In short, connecting clinical behaviour to these complex molecular and genetic profiles is an ongoing challenge.
Genomic instability drives human genome evolution, both in healthy and disease states, and it is common in many forms of cancer 81 . Hyperdiploidy reflects chromosome-segregation failure during mitosis 82 . Telomere dysfunction, DNA-repair defects and chromothripsis (the acute shattering of genomic regions) are possible mechanisms of genome instability. Defects in the p53 pathway, loss of genes mapping to 1p and 11q or gains of genes mapping to 1q and 17q may also have a role 49 . DNA index in the hyperdiploid range, which is typical for low-risk neuroblastoma, confers favourable outcome 83 . However, we do not know whether hyperdiploidy is simply a genomic biomarker or whether some mechanism links ploidy, neuroblastoma-cell differentiation and outcome. Patients whose high-risk tumours harbour large segmental chromosomal lesions fare much worse 84 . Established markers of poor prognosis include losses of 1p 85 and 11q 86 and gain of 17q 87 ; losses of 3p, 4p, 9p and 14q, and gain of 1q, 2p, 7q and 11p have also been implicated 88 . The loss of 11q is associated with an older age at diagnosis, absence of MYCN amplification and more chromosomal breaks. Because breakpoints occur on multiple chromosomes, they probably reflect an underlying defect in DNA maintenance or repair 84 or increased levels of double-stranded DNA breaks as a result of the abnormal cellular physiology of neuroblastoma.
Chromosome instability is a dynamic process that cannot be accurately measured at a single time point. It is important to distinguish between dynamic processes that reflect the continuous accumulation of genetic lesions and more acute genomic events such as multiple chromosome trisomies in hyperdiploid neuroblastoma or chromothripsis 89 . Chromothripsis, which occurs in 2% to 3% of human cancers, may result from the uncoupling of DNA replication between individual chromosomes in micronuclei and those in the nucleus. If a chromosome in the micronucleus is still replicating its DNA when the cell enters mitosis, a massive break can occur that is limited to that chromosome. In a wholegenome sequencing study of neuroblastoma, the investigators identified structural variants consistent with chromothripsis in 18% of high-risk neuroblastomas 4 . In a separate study of 40 stage 4 neuroblastomas, there was only one tumour with evidence of chromo thripsis 5 . Thus, additional studies are required to elucidate the frequency and importance of chromothripsis in neuroblastoma.
Immunology and immunotherapy
Because neuroblastomas can spontaneously regress, de novo antitumour immunity in patients seems logical. However, an active adaptive immunity against neuroblastoma has been difficult to demonstrate, especially in high-risk patients. This is not unexpected given the exceptionally large tumour bulk (both primary and metastatic) and its rapid proliferation, which can overwhelm the immature immune system in a child. The paucity of somatic mutations in neuroblastoma makes it poorly immunogenic. In addition, neuroblastoma has built a sophisticated immunosuppressive microenvironment that prevents the development of effective T cell immunity.
Neuroblastoma escapes the immune system. Neuroblastoma cells evade T cells and natural killer (NK) cells by downregulating human leukocyte antigen (HLA) 90, 91 and adhesion molecules 92, 93 . They express or release proteins to inhibit [94] [95] [96] [97] [98] and kill T cells and NK cells 99 . They even recruit tissue macrophages to disable these lymphocytes 100 . Neuroblastoma cells carry on their surface high levels of gangliosides and sialic acidcontaining sugars and proteins 65 , which are important for migration, adhesion and metastasis 101 . negatively charged carbohydrate epitopes are poorly immunogenic 102 and sometimes even immunosuppressive 103 . Natural antibodies against neuroblastoma are rare, with the possible exception of immunoglobulin M (IgM) 104 . Natural anti-ganglioside antibodies are even rarer, thereby allowing neuroblastomas to survive in the circulation despite their lack of complement decay accelerating factor (CD55) 105 . In addition, neuroblastomas can exploit protectin (CD59) to resist complement-mediated cytotoxicity (CMC) 106 . Although neuroblastomas downregulate HLA to escape T cells, ironically they can also re-express HLA to resist NK cell-mediated antibodydependent cell-mediated cytotoxicity (NK-ADCC) when treated with monoclonal antibodies (MAbs) 107, 108 . This duplicity highlights the plasticity of neuroblastoma as treatment pressures are applied. Clinically, neuroblastoma evades the immune system by escaping to sanctuaries such as the CNS, which is not accessible to circulating antibodies. In fact, the increasing frequency of isolated relapses in the CNS, in soft tissues (for example, lymph nodes) and in bone (despite the marrow space being in remission) signals a new curative challenge in the era of MAb therapy 108 .
Neuroblastoma vaccines to stimulate T cell-mediated immunity. Given these escape mechanisms and the complexity of T cell-mediated immunity 109 , constructing an effective T cell vaccine is daunting. Neuroblastoma antigens recognizable by cytotoxic T lymphocytes (CTLs) 110 exist; they include cancer-testes antigens (melanoma-associated antigen (MAGE) and NY-ESO1 (also known as CTAG1B) 111 ), MYCN 112 and survivin 91 . However, despite compelling evidence that T cell vaccines using these antigens can be effective in syngeneic mouse models 113, 114 , clinical success has been limited 115 . The use of dendritic cells as T cell vaccines is still in early clinical testing 116 . Until the patient's weak T cell immunity following high-dose chemotherapy can be recharged, strategies to circumvent T cell blockades (for example, antibodies against CTL-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) 117 ) may not be effective.
Anti-GD2 monoclonal antibodies.
The discovery that high-risk patients with neuroblastoma can be maintained in continual remission with GD2-specific MAb therapy was unexpected and is rapidly becoming the standard of care after two decades of research (FIG. 3) . GD2 belongs to a unique class of T cell-independent carbohydrate antigens with high density 66 , membrane proximity, homogeneity within and across neuroblastomas, and rare occurrence of antigen loss 118 . As an oncofetal antigen, GD2 is expressed during fetal development and in mature neurons, pain fibres and skin cells. Two intravenous (i.v.) anti-GD2 IgG antibodies have been tested extensively in the clinic: chimeric 14.18 (ch14.18) 119 and mouse 3F8 (REFS 108,120) (TABLE 2). Ch14.18 combined with i.v. interleukin-2 (IL-2) and i.v. granulocyte-macrophage colony-stimulating factor (GM-CSF), plus oral 13-cis-retinoic acid, was proved efficacious in a randomized trial 119 . The use of 3F8 plus subcutaneous GM-CSF and oral 13-cis-retinoic acid without IL-2 in a single arm study showed a 5-year progression-free survival rate of 62% and overall survival of 81% among patients with high-risk stage 4 neuro blastoma treated in first remission 108 , although its true efficacy cannot be certain without a randomized control design. The pain side effects have constrained the anti-GD2 MAb dose, and efficacy has only been observed to date in patients with minimal residual disease and has rarely been seen in patients with bulky neuroblastoma. Persistent minimal residual disease and gangliosides) are constantly released into the tumour stroma to impair cellular immunity. Moreover, neuroblastoma recruits protumour macrophages and silences natural killer (NK) cells. Myeloid suppressor cells and regulatory T cells can also suppress immunity. The paucity of mutations in neuroblastoma compared with adult cancers, such as melanoma, the immaturity of the immune system in young patients, the high disease burden in these patients and the intensive use of chemotherapy all combine to make neuroblastoma poorly immunogenic for T cells. Carbohydrate differentiation antigens (for example, GD2, GD3, their O-acetylated forms 67 and polysialic acid (PSA) 142 ), all of which are classically T cell-independent antigens, offer alternative targets for antibody-based therapies. In the presence of monoclonal antibodies (for example, 3F8 or chimeric 14.18 (ch14.18)) specific for GD2, neuroblastoma loses its defence and becomes highly susceptible to NK cell-mediated antibody-dependent cell-mediated cytotoxicity (NK-ADCC); granulocyte-mediated ADCC (granulocyte-ADCC); complement-mediated cytotoxicity (CMC) by binding to C1q (thereby activating the complement cascade and delivering membrane attack complex (MAC) to the tumour cell membrane); and monocyte-macrophage mediated cytotoxicity (phagocytosis). Even polyclonal T cells can be retargeted to kill neuroblastoma through monoclonal antibodies in the form of chimeric antigen receptors (CARs) or bispecific antibodies (anti-GD2 and anti-CD3). CARs are antitumour single chain Fv fragments (scFvs) genetically fused through a transmembrane domain to T cell-activating motifs (CD3ζ and CD28 or 41BB) and transfected into killer lymphocytes. ALK, anaplastic lymphoma receptor tyrosine kinase. 
Granulocyte ADCC
Killing of tumour cells by granulocytes, the Fc receptor of which adheres to the antibody already attached to the target cell.
Killer cell immunoglobulin-like receptors
(KIRs). Highly polymorphic natural killer cell surface proteins that interact with major histocompatibility complex class I molecules. Most KIRs mediate natural killer cell inhibition instead of activation.
β-glucan
Polysaccharides of d-glucose monomers linked by β-glycosidic bonds. β-glucan (1,3/1,4 linkages) from cereals such as barley or β-glucan (1,3/1,6 linkages) from mushroom and yeasts bind to the dectin 1 receptor and complement receptor 3 (CR3 or CD11b/CD18) and enhance receptor-mediated antitumour properties.
Regulatory T cells (T Reg cells). A T cell subtype that releases suppressive cytokines and silences immune responses.
early during immunotherapy was highly predictive of ultimate treatment failure 108 . Granulocyte ADCC 121 and NK-ADCC 107 are important effector mechanisms. A better understanding of the immunology of anti-GD2 MAb therapy should help to explain its success and offer future directions. Anti-GD2 MAbs do much more than passively attach tumour cells to NK cells; they rescue NK cells from being suppressed or inhibited by neuroblastoma. Normally, inhibitory receptors on NK cells (for example, killer cell immunoglobulin-like receptors (KIRs)) efficiently 'brake' the network of synergizing activating receptors 122 until Fcγ receptor III (FcγRIII) (also known as CD16)-mediated signalling releases that brake. KIR genes and HLA genes (which encode the cognate KIR ligands) are polymorphic and segregate independently; some individuals (up to 60%) have KIRs on their NK cells with no corresponding HLA ligands during maturation 123, 124 . These cells with missing inhibitory KIR ligands are 'uneducated' and hyporeactive until their CD16 is activated during ADCC. Conversely, 'educated' NK cells are restrained by tumour HLA, which is upregulated by cytokines released during ADCC. This restraint by HLA explains why patients with 'missing inhibitory KIR ligands' have a better outcome following anti-GD2 MAb therapy 107, 108, 123, 124 . In a similar way to NK cells, myeloid effectors are awakened by anti-GD2 MAb therapy. Granulocyte-ADCC of neuroblastoma is unique among cancers and is clinically important 108, 125 . It does not depend on oxidative intermediates 126 , requires azurophil (primary) granule exocytosis 125 and is enhanced by GM-CSF 125, 127 . Among FcγRs, FcγRIIA (also known as CD32) is the receptor for ADCC on granulocytes 125, 128 , and its affinity for anti-GD2 MAb correlates with patient outcome 124, 129 . In addition to FcγR, the complement receptors CR3 and CR4 on granulocytes are crucial adhesion molecules for this type of ADCC 125, 128, 130 . One of their natural ligands is membranebound C3bi, which is a breakdown product of C3 that results from complement activation on neuroblastoma cells 130 . When activated, CR3 acquires the conformational neoepitope CBRM1/5 (REF. 131 ), and this is correlated with better patient survival 121 , especially in the presence of high-dose GM-CSF administered subcutaneously 108 . β-glucan binds and activates CR3 and, when administered orally, enhances antibody therapy of neuroblastoma 132 . Tumour-associated macrophages (TAMs) represent another class of myeloid effector gaining prominence in neuroblastoma research 133 . Macrophage migration inhibitory factor regulates neuroblastoma growth, angiogenesis and metastasis 134 and is associated with dedifferentiation in MYCN-amplified tumours 135 . Depending on the microenvironment, TAMs can become polarized into type 1 antitumour or type 2 protumour phenotypes 136 . In the presence of anti-GD2 MAb in vitro, ADCC can turn protumour M-CSF-activated macrophages into efficient antitumour 'killing machines' (REF. 137 ).
ADCC requires leukocytes, which are typically depleted following induction chemotherapy or autologous stem cell transplants. Moreover, ADCC is most efficient when effector leukocytes are activated by cytokines. With their ability to multiply the number and the efficiency of NK cells and granulocytes, IL-2 and GM-CSF are obvious candidates for respective combinations with anti-GD2 MAbs. IL-2, which activates NK cells, natural killer T (NKT) cells, T cells and the undesirable regulatory T cells (T Reg cells) 138 , has a modest anti-neuroblastoma effect as a single agent 139 . Unlike GM-CSF, IL-2 is associated with substantial toxicity (for example, 23% of patients experienced capillary leak 119 146 . Despite compelling data in syngeneic mouse models 147 , i.v. hu14.18-IL-2 produced bone marrow remission only if neuroblastoma was minimal 145 , and no benefit was seen for soft-tissue tumours 145, 148 . The clinical advantage of hu14.18-IL-2 over ch14.18 plus IL-2 awaits confirmation because grade 3 and grade 4 capillary leak with abnormal liver functions have been seen in both 119, 145 . These considerations provide further rationale to consider IL-15 as an alternative to IL-2 for combination with anti-GD2 MAbs in neuroblastoma.
Even though MAb therapy is often regarded as passive immunotherapy, the induction of a host antitumour or anti-idiotype network following MAb therapy may be important for long-term tumour control 149 . Human anti-mouse antibody response (HAMA), an indirect measure of the host anti-idiotype network, was consistently correlated with long-term survival in patients treated with anti-GD2 MAbs 108, 149 . Because of these observations, anti-idiotypic vaccines such as mouse IgG1 antibody 1A7 specific for ch14.18 (REF. 150) and rat IgG1 antibody A1G4 specific for 3F8 seem logical 151 . The GD2 peptide mimotope 152 and its DNA vaccine 153 can induce serum antibodies and protective anti-GD2 IgG responses in mice. However, in contrast to whole-antigen vaccines, single-epitope vaccines will probably be limited by their narrow target coverage. The whole GD2 antigen has also been conjugated to keyhole limpet haemocyanin (KLH) to overcome the poor immunogenicity of carbohydrates 102 . Besides its use as a target to direct leukocyte-mediated killing, GD2 is also ideal for tumour-selective delivery of radioisotopes, liposomes or nanoparticles 69 . However, the pain side effect 108, 119 , which is thought to be a consequence of complement activation 154 , is a major limitation of anti-GD2 MAb therapy. Mutating the Fc region to reduce complement activation 154 and using blocking antibodies 155 have decreased but not eliminated pain. Humanized 3F8 (hu3F8) has The B7-H3-specific MAb 8H9 has been used successfully for compartmental radioimmunotherapy of neuroblastoma metastasis to the CNS 160 .
Adoptive T cell therapy. The new paradigm of including T lymphocytes in MAb therapy of neuroblastoma is taking shape. Although autologous tumour-reactive T cells are rare in patients with neuroblastoma and fail to home to tumour sites 91 , genetically redirected T cells (directed, for example, by chimeric antigen receptors (CARs)) hold great promise 161, 162 . CARs connect a single-chain variable fragment (scFv) (anti-GD2) with a T cell intracellular-signalling domain. When they were virally transfected into activated T cells (ATCs), clinical benefit was seen in neuro blastoma 162 . CARs built with anti-L1CAM (MAb CE7) have been tested in neuroblastoma, although the persistence of ATCs expressing these CARs was shortlived (≤42 days) 161 . To enhance the survival of these T cells, Epstein-Barr virus (EBV)-specific CTLs have been successfully used instead of polyclonal ATCs, as EBV-CTLs are subject to continuing antigenic challenge 162 . These dual-specific CTLs (anti-EBV through the natural T cell receptor and anti-GD2 through the CAR) can persist and exert tumour control for years 162 . Additional possible genetic modifications include luring T cells with chemokine receptors 143, 163 , reducing T Reg cell interference by enhancing activation of the AKT pathway 164 , adding co-stimulatory signals to new-generation CARs and introducing suicide genes in case there are unanticipated major toxicities 165 . The future of neuroblastoma immunotherapy. The current immunotherapy strategy uses anti-GD2 MAbs to direct the traffic of FcγR-bearing NK cells and granulocytes, stimulating them through the FcγRs CD16 and CD32, respectively. However, by activating through CD3, CAR-modified T cells or T cell-engaging bispecific antibodies (anti-GD2 and anti-CD3) can exploit T cells that do not carry FcγRs 168 ; such T cells are underused effectors that have the potential to generate long-term antitumour immunity. As the Fc function is not required for bispecific MAbs and is therefore dispensable, the pain side effects of anti-GD2 antibodies could potentially be eliminated. A rational combination of antitumour MAbs, effector cells and cytokines to induce tumour cell death along with small molecules to prevent death evasion can be tested in appropriate mouse models to guide ongoing and future clinical trials.
Translational model
Genetic and epigenetic aberrations carried by highrisk neuroblastoma are continually exploited by these tumours to survive the selective pressures of competing nutrients, hypoxia, immune surveillance and cytotoxic therapy. Immune surveillance and cytotoxic therapy have successfully been applied to neuroblastoma and have shown the potential of a cure, but not for all patients. With cytotoxic therapy, increasing dose and dose intensity have been explored 169, 170 , and such treatment could be further maximized with better supportive care. Small molecules that target specific genetic and epigenetic aberrations are rapidly transitioning into the clinic for neuroblastoma (TABLE 2) . ALK is an exemplary tumour target for neuro blastoma therapy 39 , ahead of other promising gene candidates (FIG. 2) .
Translational and clinical research of paediatric cancers is fundamentally different from that of adult cancers because there are relatively few patients and clinical trials are often carried out by cooperative groups. Also, drug metabolism, acute toxicities and late effects vary greatly between children and adults. Most paediatric preclinical cancer studies use cell lines or flank xenografts in immunocompromised mice 171 . For immunological analysis, mouse effectors are poor human surrogates for testing MAbs 172 ; humanized mice (TABLE 3) -that is, immunodeficient mice grafted with immunocompetent human immune cells -should be more appropriate 173, 174 . Many research groups incorporate genetically engineered mouse models 175 , but few use comprehensive preclinical studies to directly guide clinical trials 176 . For example, most studies are short-term (2-3 weeks), using drug doses and schedules that are not clinically relevant. They often fail to incorporate combination chemotherapy and do not have an appropriate benchmark (for example, the current standard of care). Most preclinical studies also lack statistical design, appropriate randomization of animals to treatment regimens and/or a mechanism to 'blind' researchers to treatments received by study cohorts. An ideal translational research 'roadmap' (BOX 1) should engage a multidisciplinary team comprising clinical researchers, laboratory-based scientists, chemists, pharmacologists and biostatisticians.
With the exception of ALK, genomic characterization of neuroblastoma has provided few leads for druggable pathways that can be directly moved into clinical trials. We propose that a multipronged approach will be required to improve outcomes for patients with neuroblastoma over the next decade. As presented here, neuroendocrine differentiation of neuroblastomas can be exploited in two ways. First, epigenetic processes are important for coordinating proliferation and differentiation during development. In other paediatric cancers with features of neuronal differentiation, such as retinoblastoma, epigenetic profiling provided important new insights into tumour initiation and progression and led to the identification of novel therapeutic approaches 177 . Therefore, epigenetic profiling of neuroblastomas may help to identify differentiation or cancer pathways that can be targeted in the clinic. Second, it may be possible to exploit the unique features of neuroblastoma differentiation with respect to catecholamine biosynthesis, transport and metabolism by using therapeutics to force intracellular accumulation of toxic catechoaldehydes or other perturbations. Another approach is to identify novel therapeutics using an unbiased high-throughput drug screening, as recently used for paediatric brain tumours 178 . For such approaches, it is essential to have validated cellbased screening assays that faithfully recapitulate the molecular, cellular and genetic heterogeneity of neuro blastoma found in patients. Although small molecules used in single-agent-targeted strategies will provide proof of principle, their curative potential in neuroblastoma is likely to require the exploitation of multiple pathways and careful integration with active death induction through either chemoradiotherapy or immunotherapy.
Overall conclusion
We have witnessed tremendous advances in our understanding of the genetics and biology of neuroblastoma that will greatly improve the precision with which this complex heterogeneous disease can be stratified. There have also been remarkable advances in our understanding of how neuroblastoma tumour cells evade the immune system, and some of the most promising therapeutic approaches for neuroblastoma now involve immunotherapy. With the ability to further refine the classification of patients accurately into risk groups 3 , the challenge we face in the next decade is to identify the most effective and least toxic therapy for these patient subgroups. The focus must now shift towards multidisciplinary translational research teams using validated preclinical models to select the most promising combinations of molecularly targeted therapies, broad-spectrum chemotherapy and immunotherapy to cure patients who currently have a poor prognosis and to reduce therapy for those with more favourable outcomes. Emphasis on targeted therapies and the reduction of cytotoxic treatments are the overarching goals -to cure neuroblastoma while sparing young children adverse treatment-related late effects.
Box 1 | Translational research roadmap
Step 1: identify key clinical challenges For neuroblastoma, this may include patients with high-risk disease, with a particular emphasis on those with refractory disease. It may also include patients who have very good prognosis, where translational research may reduce treatment intensity and treatment-associated toxicities.
Step 2: identify druggable targets and pathways In addition to specific kinases (for example, anaplastic lymphoma receptor tyrosine kinase (ALK)) or enzymes (for example, drug transporters), entire pathways and cellular programmes (for example, alternative lengthening of telomeres) should be considered. In some cases, biomarkers (for example, GD2) can be used for molecularly targeted therapeutics, even if the marker is not directly related to perturbations in the cellular pathways required for tumorigenesis.
Step 3: well-designed preclinical testing For orphan diseases, only the most promising new agents should move forwards, and every available resource should be used to compare and contrast that agent with the standard of care. A comprehensive preclinical trial should consider genetic mouse models and orthotopic xenografts of human primary tumours to establish the relative efficacy of competing treatment options. The choice of mouse models (TABLE 3) is crucial, especially when immunologics are being tested, human immune cells are required and the tumour microenvironment is part of the pathway being tested. Ideally, mice should undergo the same diagnostic testing (magnetic resonance imaging, ultrasound or positron emission tomography) and functional assessments (blood counts and chemistries, and urine catecholamine monitoring) that patients receive. Minimal residual disease measurement using blood samples is another potentially informative end point.
